

Frederick William Miller, M.D., Ph.D.

Curriculum Vitae, August 2011

PERSONAL INFORMATION

Business Address

Chief, Environmental Autoimmunity Group
Office of Clinical Research
National Institutes of Environmental Health Sciences (NIEHS)
National Institutes of Health, DHHS
Clinical Research Center, Rm. 4-2352
10 Center Drive, MSC 1301
Bethesda, MD 20892-1301

Phone: 301-451-6273

Fax: 301-451-5585

Email: millerf@mail.nih.gov

Website: <http://www.niehs.nih.gov/research/clinical/ea/index.cfm>

MAJOR RESEARCH INTERESTS

Genetic and Environmental Risk Factors and Pathogenesis of Immune-mediated Diseases

Outcome Assessment and Therapy of Autoimmune Disorders

EDUCATION

- | | |
|------|--|
| 1979 | M.D., Ph.D., Medical Scientist Training Program, Department of Anatomy and Developmental Biology Center, Case Western Reserve University School of Medicine, Cleveland, OH |
| 1973 | B.A., Zoology, with minor in Chemistry, <i>Summa cum laude</i> , General Honors, Miami University, Oxford, OH |
| 1969 | Salutatorian, Troy High School, Troy, OH |

PROFESSIONAL EXPERIENCE

- | | |
|------------|---|
| Since 2001 | Chief, Environmental Autoimmunity Group, Office of Clinical Research, DIR, NIEHS, NIH, Bethesda, MD, Tenured Senior Investigator, Captain, US Public Health Service Research Officer Group. |
|------------|---|

- 11/96-2000 Senior Investigator and Medical Officer – Clinical and Product Reviewer, Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, CBER, FDA, Bethesda, MD.
- 10/93-10/96 Senior Investigator and Medical Officer – Clinical and Product Reviewer, Molecular Immunology Laboratory, Division of Cellular and Gene Therapies, CBER, FDA; Tenured Senior Investigator, US Public Health Service Research Officer Group 1994.
- 12/90-9/93 Senior Investigator and Medical Officer - Clinical and Product Reviewer, Division of Biochemistry and Biophysics, CBER, FDA, Bethesda, MD.
- 8/86-11/90 Senior Staff Fellow and Clinical Associate - Arthritis and Rheumatism Branch, NIAMS, NIH, Bethesda, MD.
- 7/83-7/86 Medical Staff Fellow (Rheumatology Fellowship) - Arthritis and Rheumatism Branch, NIAMS, NIH, Bethesda, MD.
- 7/81-6/83 Medical Resident - Department of Medicine, Stanford University Medical Center, Stanford, CA.
- 7/80-6/81 Clinical Research Fellow - Clinical Research Facility, Emory University Medical Center, Atlanta, GA.
- 7/79-6/80 Medical Intern - Department of Medicine, Emory University School of Medicine Affiliated Hospitals, Atlanta, GA.

BOARD CERTIFICATIONS

Subspecialty Certification in Rheumatology (10/1990 and 10/2000)

American Board of Internal Medicine (10/83)

National Board of Medical Examiners (7/80)

MEDICAL LICENSURE

Maryland	#D30329	(9/83)
California	#45861	(10/81, inactive)

SELECTED PROFESSIONAL SOCIETIES

Fellow, American College of Physicians
 Fellow, American College of Rheumatology
 Member, American Association of Immunologists
 Member, the Society for Clinical and Translational Science
 Member, International Myopain Society
 Member, Henry Kunkel Society
 Member, District of Columbia Rheumatism Society
 Member, American Association for the Advancement of Science

SELECTED PROFESSIONAL HONORS AND RECOGNITION

2008	Selected for listing in American Men and Women of Science
2007	Hero Award, the Cure Juvenile Myositis Foundation, for "Dedication to Finding a Cure for Juvenile Myositis"
2005	The Dunlop-Dotteridge Lectureship, Canadian Rheumatology Assoc., Mt. Tremblant
2005	NIH Merit Award for participation on the NIEHS Strategic Planning Workgroup
2003	The Kovacs Lectureship, the Royal Society of Medicine, London
2000	Elected member of the Henry Kunkel Society
2000	First elected to Best Doctors in America
1999	US Public Health Service Meritorious Service Medal
1999	US Public Health Service Outstanding Unit Citation
1998	US Public Health Service National Vaccine Program Award
1998	US Public Health Service Unit Commendation Medal
1997	FDA Office of Woman's Health Grant recipient
1994	Elected Fellow, American College of Rheumatology
1992	FDA Office of Woman's Health Grant recipient
1989	William R. Felts Award for Excellence in Rheumatology Research
1986	American College of Rheumatology Senior Fellow Research Award
1985	Elected Fellow, American College of Physicians
1979	Hughes Research Award, Case Western Reserve University
1974-1977	National Research Service Awards, Case Western Reserve University
1973	Selected as NIH Trainee - Fertilization & Gamete Physiology Training Program, Marine Biology Laboratory, Woods Hole, MA
1973	B.A., <i>Summa cum laude</i> , General Honors, Miami University
1973	Elected to Phi Beta Kappa Honor Society, Miami University
1973	Hughes Chemistry Award, Miami University
1972	Culler Physics Award, Miami University
1971	Elected to Phi Beta Sigma Honor Society, Miami University
1971-1972	Alan Brewer Memorial Scholarships, Miami University

1969-1970 John Rawlings Memorial Scholarships, Miami University

MENTORSHIP ACTIVITIES

Directed research projects and mentored dozens of undergraduate students, graduate students, medical students, postdoctoral fellows, clinical research fellows, visiting scientists, guest workers and summer students at the Food and Drug Administration and National Institutes of Health from 1983-present.

SELECTED SCIENTIFIC LEADERSHIP AND COMMITTEE WORK

NIH, FDA and other Federal Agencies

Member, NIEHS Committee on Promotions I, 2010-present

Ad hoc Member, NIEHS Clinical Research Unit Contract Resource Review Committee, 2009-present

Chair, NIEHS Clinical Center Utilization Review Committee, 2008-present

Member, NIEHS Clinical Advisory Council, 2008-present

Member, NIEHS Strategic Planning Forum Steering Committee, 2005-2006

Member, NIH Biomedical Translational Research Information System (BTRIS) Group, 2008-present

Member, NIH Clinical Research Center Medicine Partners Committee, 2006-present

Member, NIH National Quality Forum, 2006-present

Member, NIH Translational Research Interest Group Steering Committee, 2008-present

Member, NIH Center for Human Immunology Planning Committee, 2007-present

Member, Trans-NIH Bioethics Committee, 2005-present

Member, NIH Roadmap Clinical and Translational Sciences Working Group, 2005-present

Member, NIH Roadmap Translational Core Working Group, 2003-present

Member, NIH Roadmap Regional Translational Research Center Working Group, 2003-2005

Member, NIH Chronic Graft-Versus-Host Disease Response Criteria Working Group, 2003-present

Member, NIEHS Search Committee, Staff Clinician, Clinical Research Unit, 2006

Member, NIEHS Search Committee, Tenure-Track Clinical Investigator in host defense, 2005

Member, NIEHS Search Committee, Tenure-Track Clinical Investigator in Gynecology, 2003

Member, NIEHS Search Committee, Staff Clinician, Environmental Autoimmunity Group, 2002

Alternate Member, NIH Medical Executive Committee, 2001-present

Principal Investigator, the NIEHS Environmental factors in the anti-synthetase syndrome, 2010-present

Principal Investigator, the NIEHS Rituximab in Myositis Trial, 2006-present

Principal Investigator, the NIEHS Natural History of Autoimmune Diseases Study, 2005-present

Principal Investigator, the NIEHS Twin-siblings Systemic Autoimmunity Study, 2003-present

Principal Investigator, the FDA Silicone associated Connective Tissue Disease Study, 1995-2003

Principal Investigator, the FDA Natural History of Autoimmune Diseases Study, 1993-2005

Principal Investigator, the FDA Myositis Developing after Vaccination Study, 1993-2005

Principal Investigator, the FDA Myositis Developing after Silicone Implants Study, 1993-2003

Principal Investigator, the NIAMS High Dose Methotrexate in Myositis Study, 1987- 1997

Principal Investigator, the NIAMS Apheresis in Myositis Trial, 1986-1990

Principal Investigator, the NIAMS Cyclophosphamide in Myositis Trial, 1986-1989

Principal Investigator, the FDA Myositis Developing after Vaccination Study, 1993-2006

Principal Investigator, the FDA Familial Myositis Study, 1999-2002

Principal Investigator, the FDA Myositis Developing after Silicone Implants Study, 1993-2003

Principal Investigator, the FDA Myeloma and MGUS following Silicone Implants Study, 1993-2003

Associate Investigator, the NIEHS Natural History of Adult and Juvenile Myositis Study, 2001-present

Associate Investigator, the NIAMS Infliximab in Myositis Study, 1999-present

Associate Investigator, the NIAMS Natural History of Myositis Study, 1985-present

Associate Investigator, the NIAMS Familial Autoimmunity Study, 1988-1993

Associate Investigator, the NIDR Soft Tissue Calcification Study, 2002-2008

Associate Investigator, the FDA Rheumatoid Arthritis after Lyme Vaccine Study, 2001-2009

Member, FDA Rheumatology Working Group, 1994-2002

Member, FDA Vascular Injury Expert Working Group, 2000-2004

Member, DHHS Silicone Breast Implant Research Task Force, 1992-1999

Member, Armed Forces Institute of Pathology Scientific Advisory Board, Washington, DC, 1996-2000

Member, DHHS Interagency Temporal Mandibular Disorder Working Group, 1997-2002

Reviewer, Veterans Administration Research Merit Review Board, 1999-2002

Member, IRB Committee, Walter Reed Army Medical Center, Washington DC, 1994-1998

Medical Staff Guest Worker, Principal Clinical Investigator, NIH Clinical Center, Arthritis and Rheumatism Branch, NIAMS, 1990-2001

Elected representative, Committee to Advance CBER Science, FDA, 1996-2000

Clinical IND and BLA Reviewer, Division of Clinical Trials, CBER, FDA, 1994-2002

Product IND and BLA Reviewer, Division of Cell and Gene Therapy and Div. of Monoclonal Antibodies, CBER, FDA, 1990-2002

Chair, FDA Biologics Licensing Application Committee, Simulect™, 1997-1998

Chair, FDA Electronic IND (eIND) Working Group, 1995-1999

Chair, FDA Gene Therapy Information Network Working Group, 1993-1995

Chair, Rheumatology Focus Group, Division of Clinical Trials, CBER, FDA, 1992-1995

Member, FDA IND Communications Working Group, 1996-1998

Project leader and author, FDA Guidance to Industry regarding the pilot eIND Program, 1993-1999

Project member and co-author, FDA Guidance to Industry regarding developing therapies for rheumatoid arthritis, 1998

Project member and contributing author, FDA Guidance to Industry regarding electronic submissions of patient case report forms and case report tabulations, 1997

Member, FDA FiRST Initiative, 1996-2000

Advisor, FDA Office of the Commissioner and FDA Centers Coordination Committee – focusing on regulatory issues relating to autoimmunity and genetic risk factors for adverse events, 1990-2002

Nationally and Internationally

Member, Connective Tissue Disease Related Interstitial Lung Disease Special Interest Group, 2009-present

Chair, The International Myositis Assessment and Clinical Studies Group (IMACS) Research Review Committee, 2008-present

Co-founder and Co-director, The Pan-American Congress of Rheumatism (PANLAR) Myositis Consortium, 2007-present

Founder and Director, The Myositis Genetics Consortium (MYOGEN), 2006-present

Member, Scientific Work Group, Natl. Conversation on Public Health and Chemical Exposures, 2009-present

Category Chair, Myopathies, American College of Rheumatology National Meeting Abstract Selection Committee, 2005-2006 and 2010-2011

Co-organizer and Member, Steering Committee, ACR-EULAR International Myositis Classification Criteria Project, 2003-present

Founder and Director, the Environmental Myositis Collaborative Study Group, 2000-present

Co-founder and Co-Director, The International Myositis Assessment and Clinical Studies Group (IMACS), 2000-present

Co-founder, the Childhood Myositis Heterogeneity Collaborative Study Group 1995-present

Co-founder, the Childhood Myositis Disease Activity Collaborative Study Group, 1995-present

Member, National Conversation on Public Health and Chemical Exposures, Scientific Understanding Work Group Membership, 2009-present

Member, Publications Committee, the NIAMS Rituximab in Myositis Trial, 2009-present

Member, Research Review Committee, The NIAMS Rituximab in Myositis Trial, 2004-present

Member, Adjudication Committee, The NIAMS Rituximab in Myositis Trial, 2004-present

Member, Steering Committee, The NIAMS Rituximab in Myositis Trial, 2002-present

Scientific reviewer, The Myositis Association Grants Program, 2004-present

Member, Nominations Committee, The Myositis Association, 2007-2008

Member, Medical Advisory Board, The Myositis Association, 2000-2008

Member, Board of Directors and Medical Advisory Board Vice-Chair, The Myositis Association, 2000-2004

Invited presenter, NAS Institute of Medicine Silicone Scientific Review Committee, 1998

Member, OMERACT Toxicity Assessment Task Force, 1996-2003

Founder and Chair, American College of Rheumatology Environmentally-Associated Rheumatic Diseases Study Group, 1994-99

Member, ACR National Meeting Myositis Abstract Selection Committees, 1990, 1991, 1992, 1996, 1997, 1998-2001, 2004-2009

Member, Juvenile Dermatomyositis Registry Advisory Board, 1996-2003

Selected presenter, American College of Rheumatology Meet the Expert Series, Myositis and Myopathies, 1996-1998 and 2001-2003

Board Member/Advisor, the National Dermatomyositis Support Group, 1994-1996

Founder and Director, the International Myositis Collaborative Study Group, 1993-present

SELECTED ORGANIZATION OF WORKSHOPS, SYMPOSIA, CONFERENCES

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Atlanta, GA, November 7, 2010

Co-organizer, NIEHS Symposium on the Environment and Autoimmune Diseases, September 8-10, 2010, Durham, NC

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Philadelphia, PA, October 17, 2009

Co-moderator, The ACR Annual Meeting Session, *Inflammatory Myopathies: Disease Mechanisms, Biomarkers and Treatment*, San Francisco, CA, October 29, 2008.

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, San Francisco, CA, October 27, 2008

Co-organizer and co-moderator, The PANLAR Myositis Consortium meeting, Guatemala City, Guatemala, August 21, 2008

Organizer and moderator, The International Myositis Genetics Consortium (MYOGEN) planning meeting, Boston, MA, November 9, 2007

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Boston, MA, November 10, 2007

Organizer and moderator, The International Myositis Genetics Consortium (MYOGEN) organizational meeting, Washington, DC, November 13, 2006

Co-organizer and speaker, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, *Update on Myositis Clinical Studies*, Washington, DC, November 14, 2006

Co-organizer and co-moderator, The PANLAR Myositis Consortium, Organizational meeting, Lima, Peru, August 21, 2006

Co-organizer and moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, *Update on Myositis Clinical Studies and the IMACS Data Repository*, San Diego, CA, November 13, 2005

Co-organizer and moderator, *The ACR-EULAR International Myositis Classification Criteria Project Working Group Workshop*, Dulles, VA, November 10-11, 2005

Organizer and moderator, *The ACR-EULAR International Myositis Classification Criteria Project Steering Group Workshop*, Bethesda, MD, October 26, 2004

Co-organizer, 3rd International Myositis Assessment and Clinical Studies Workshop, *Planning for Myositis Clinical Studies and the IMACS Data Repository*, Orlando, FL, October 25-26, 2003

Member, Workshop Planning Committee, *Environmental Factors in Autoimmune Diseases*, National Institute of Environmental Health Sciences, Durham, NC, February 4-5, 2003.

Co-organizer, 2nd International Myositis Assessment and Clinical Studies Workshop, *Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis*, NIH Office of Rare Diseases, NIAMS, NINDS, NIEHS funded meeting, New Orleans, LA, October 22-23, 2002

Co-organizer and moderator, 1st International Myositis Assessment and Clinical Studies Workshop, *Defining Improvement in Adult and Juvenile Myositis*, NIH Office of Rare Diseases, NIAMS, NINDS, and NIEHS funded meeting, San Francisco, CA, November 9th-10th, 2001

Organizer and moderator, *Approaches for Studying Possible Associations between Vaccinations and Rheumatic Disorders*, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, Philadelphia, PA, October 20, 2000

Co-organizer and co-moderator, *NIH Workshop on Basic and Clinical Research in Inflammatory Myopathy*, NIAMS-sponsored meeting, Bethesda, MD, April 5-6, 2000

Organizer and moderator, *Defining The Environmental Causes for Autoimmune Diseases*, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, Boston, MA, November 14, 1999

Organizer and moderator, *Drug-Associated Rheumatic Diseases*, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, San Diego, CA, November 19, 1998.

Co-Organizer and moderator, *Biologic Agents for Autoimmune Diseases IV*, Washington, DC, March 1995

Co-Organizer and moderator, Immunology Session, FASEB meeting, Boston, MA. August, 1993

SELECTED EDITORIAL ACTIVITIES

Editorial Board, *The Open Rheumatology Journal*, Bentham Science Publishers Ltd., 2007 – present

Co-Editor, *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, The Myositis Association, Washington, 2007.

Section Editor, Inflammatory Myopathies, *Rheumatic Disease Clinics North America*, 2001-2002

Section Editor, Myositis and Myopathies, *Current Opinion in Rheumatology*, 1995-8

AD HOC REVIEWER FOR JOURNALS (SELECTED RECENT EXAMPLES)

Annals of Internal Medicine, American Journal of Public Health, Arthritis & Rheumatism, Arthritis Care & Research, Arthritis Research and Therapy, BMC Musculoskeletal Disorders, Clinical Immunology, Current Rheumatology Reviews, Environmental Health Insights, Expert Review of Dermatology, Journal of Clinical Investigation, Journal of Clinical Rheumatology, Journal of Immunology, Journal of Rheumatology, Journal of the European Academy of Dermatology and Venereology, Journal of the National Cancer Institute, Lancet Neurology, Lupus, Nature Medicine, Nucleic Acids Research, PLoS ONE, Proceedings of the National Academy of Science, Rheumatology, Seminars in Arthritis and Rheumatism

SELECTED INVITED LECTURES

DC Rheumatism Society Fellows Forum in Washington, DC, Plenary talk, *Myositis 2011: Past, Present and Future*, June, 2011

NIH Neuromuscular Interest Group, Bethesda, MD, *Close encounters with the myositis syndromes*, May, 2011

Advances in Targeted Therapies Meeting, Dubrovnik, Croatia, *New approaches to understanding the pathogenesis, assessment and treatment of myositis*, April, 2011

Joint Canadian-Mexican Congress of Rheumatology, Cancun, Mexico, *Update on therapies for myositis*, February, 2011

American College of Rheumatology Annual Meeting, Atlanta, GA, *Myositis 2010, A to Z*, November, 2010

New York Rheumatology Board Review Course, New York, NY, *Review of Inflammatory and other Myopathies*, October, 2010

NIH Office of Research on Women's Health Seminar Series, Bethesda, MD, *Environmental Aspects of Autoimmune Diseases*, October, 2010

Virginia Society of Rheumatology Annual Meeting, Virginia Beach, VA. *Myositis Pathogenesis, Assessment and Treatment*, October, 2010

Frontiers of Rheumatology, Mexico City, Mexico, *Close encounters with the Myositis Syndromes*, September, 2010

NIH Summer Intern Training Program Speaker Series, Bethesda, MD, *Why the Environment is Critical to Understanding Autoimmune Diseases*, July, 2010.

University of Alabama School of Medicine Grand Rounds, Birmingham, AL, *New Developments in the Diagnosis, Pathogenesis and Management of Myositis*, June 2010

Autoimmune Diseases Summit: The Global State of Autoimmunity Today, Baltimore, MD, *The Escalating Problem of Autoimmune Diseases: Investigating the Epidemic Increase in Incidence and Environmental Associations*, March, 2010

NIH Clinical Center Grand Rounds, Bethesda, MD, *Phenotypes as Clues to Deciphering the Pathogenesis and Treatment of Myositis*, February, 2010

NIH Medical-Surgical Training Program, Bethesda, MD, *Myositis 101 – The Essential Information You Need to Know to Care for Patients with Autoimmune Muscle Diseases*, November 2009.

New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, October, 2009

The First Myositis Association Research Symposium, Baltimore, MD, *The Genetics of Myositis – the search for Elemental Disorders*, January, 2009

Washington Hospital Center, Dept. of Medicine Grand Rounds, *Unweaving the Tapestry of Myositis One Patient at a Time*, Washington, DC, January, 2009

AUTOCURE 2008 Meeting, Prague, Czech Republic. *Genetic risk and protective factors for the idiopathic inflammatory myopathies*, December, 2008

University of North Carolina Rheumatology Grand Rounds, Chapel Hill, NC, *Myositis Pearls, Myths and Realities*, November, 2008

The Myositis Association Annual Meeting, Denver, CO, *The Environment and Autoimmune diseases – Where we stand in 2008*; and *Myositis Research Highlights – What have we learned in the last 15 years*. September, 2008

The 15th Pediatric Rheumatology European Society Congress, London, UK, *Dissecting Genotype-Phenotype Interactions in the Pathogenesis of Adult and Juvenile Myositis*, September, 2008

- New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, September, 2008
- NIEHS Public Interest Liaison Group Meeting, Washington, DC, *NIEHS Translational Research in the Environment and Autoimmune Diseases*, September, 2008
- The XV PANLAR Congress, Guatemala City, Guatemala, Plenary Session, *New Insights into the Pathogenesis and Management of Myositis*, August, 2008
- The Collaborative on Health and the Environment Online Presentation and Discussion Series, *Environmental Factors in the Pathogenesis of Systemic Autoimmune Diseases*, July, 2008
- Saint Louis University Medical Center Grand Rounds, *Deconstructing Myositis – What we Know, What we Think we Know and What we Need to Know*, St. Louis, MO, May 2008
- The Hospital for Special Surgery Grand Rounds, *Close Encounters with the Myositis Syndromes*, New York, NY, April 2008
- The 10th International Workshop on Autoantibodies and Autoimmunity, Guadalajara, Mexico, *Environmental Aspects of Autoimmunity*, March, 2008
- Cure Juvenile Myositis Meeting, Washington, DC, *Genetics of Myositis – Current Status and New Opportunities*, October, 2007
- New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, September, 2007
- MYOPAIN 2007, Washington, DC, *Disorders of Muscle Inflammation – Pathogenic Insights from Environmental and Epidemiologic Studies*, August, 2007
- Puerto Rican Rheumatologist's Association International Meeting, San Juan, Puerto Rico. *Dissecting Genotype-Phenotype Interactions in Myositis*, May, 2007
- 6th International Rheumatology Symposium, Yokohama, Japan, *Adventures in Inflammatory Muscle Diseases*, April, 2007
- The Myositis Association Medical Advisory Board Annual Meeting, Washington, DC, *Research Progress and Opportunities in Polymyositis and Dermatomyositis*, January, 2007
- American College of Rheumatology Annual Meeting, Washington, DC, ACR Clinical Symposium, *Developments in Myositis Response Criteria*, November, 2006
- New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, September, 2006
- XIV Congress of the Pan-American League of Associations for Rheumatology (PANLAR) Lima, Peru, *Defining Risk Factors and Pathogeneses in Inflammatory Muscle Disease*, August, 2006
- NIEHS Translation of Environmental Health Sciences Retreat, Chapel Hill, NC, *Intramural Clinical Research and Approaches to Enhancing Translational Studies*, June, 2005
- The Annual European League of Associations for Rheumatism (EULAR) Congress of Rheumatology, Vienna, Austria, *Environmental Factors in Muscle Weakness*, June, 2005
- Canadian Rheumatology Association National Meeting, Mont Tremblant, Quebec, The Dunlop-Dotteridge Plenary Lecture: *Close Encounters with the Myositis Syndromes*, March, 2005
- NIEHS Division of Intramural Research Retreat, New Bern, NC, Mini Symposium *Environmental Aspects of Immune-Mediated Diseases*, October, 2004

NIAID Eosinophilia Myalgia Syndrome (EMS) Conference, Bethesda, MD. *Genetic risk and protective factors for EMS*, October 2004

The Myositis Association Annual Conference, Las Vegas, NV, *Talking with your Doctor about Myositis* and *Myositis 101, What Patients Need to Know*, and *Myositis Research Update*, August, 2004

Myopain 2004, Annual Meeting of the International Myopain Society, Munich, Germany, Plenary lecture: *Deconstructing Myositis – From Bedside to Bench and Back Again*, July, 2004

Clinical Immunology Society (CIS) Spring School in Systemic Autoimmune Diseases Meeting, Santa Fe, New Mexico, *Environmental and Genetic Aspects of Autoimmune Diseases: The Case for Elemental Disorders*, March, 2004

American College of Rheumatology Annual Meeting, Orlando, FL, *Meet the Expert Session on Myositis and Myopathies*; October, 2003

The Myositis Association Annual Conference, Houston, TX, *Translational Research on Myositis, from Bench to Bedside*, October, 2003

NIEHS Public Interest Liaison Group Meeting, New York, NY, *Autoimmune Disorders and Environmental Factors*, September, 2003

The UK Myositis Support Group Annual Meeting, Birmingham, UK, *Genetic and Environmental Risk Factors for Myopathies*, June 2003

Frontiers of Rheumatology - 21st Annual Carl M. Pearson Memorial Symposium, Huntington Beach, CA, *Differential Diagnosis of Muscle Disease: How Useful are Genetic Markers, Myositis Antibodies and Imaging Studies?* and *Optimizing the Benefit/Risk Ratio in the Management of Inflammatory Myopathies*, May, 2003

The Henry Kunkel Society 11th Annual Meeting, New York, NY, *Global Surface Ultraviolet Radiation Intensity Modulates the Clinical and Immunologic Expression of Autoimmune Muscle Disease*, April, 2003

The Royal Society of Medicine Kovacs Lectureship, London, UK, *Myositis: Aetiology and management*, March, 2003

NIEHS Conference on Environmental Factors in Autoimmune Disease, Durham, NC, *Gene-Environment Interactions in Autoimmune Diseases*, February, 2003

Mexican Society of Rheumatology Meeting, Nuevo Leon, Mexico, Plenary talk: *News and Views on Managing Polymyositis and Dermatomyositis*, February, 2003

American College of Rheumatology Annual Meeting, New Orleans, LA, *Meet the expert session on myositis and myopathies*, and Environmentally Associated Rheumatic Diseases Study Group Session, *Approaches to Evaluating Myopathies in Patients on Lipid-lowering Agents*, October, 2002

The Myositis Association of America Annual Conference, Atlanta, GA, *How we diagnose Myositis; and Myositis overlap syndromes*, September, 2002

Michigan Rheumatism Society Bi-Annual Meeting, Ann Arbor, MI, Special lecture – *Inflammatory myopathies through the looking glass of the myositis-specific autoantibodies*, June, 2002

University College, 2nd International Myositis Workshop, London, UK, *Approaches to Assessing Disease Activity and Damage in Myositis*, May, 2002

The International Myopain Society, Scientific Interdisciplinary Working Group Annual Meeting, Munich, Germany, Plenary session: *News and Views on Inflammatory Myopathies*, May, 2002

American College of Rheumatology Annual Meeting, San Francisco, CA, *Meet the Expert Session on Myositis and Myopathies*, November, 2001

The Myositis Association of America Annual Conference, San Diego, CA, *New Directions in Myositis Research*, October, 2001

University of Pittsburgh School of Medicine, Department of Medicine Grand Rounds, Pittsburgh, PA. *Update on Clinical Presentation, Diagnosis, Pathogenesis and Management of Myositis*, March, 2001

WHO Exploratory Meeting of Epidemiology of Occupational and Environmental Factors Associated with Autoimmunity, Bilthoven, the Netherlands, *Epidemiologic Studies of Autoimmune Diseases and the Environment*, May, 2000

Federal Interagency Working Group on Women's Health and the Environment Conference, DHHS, Washington, DC, *Genetic and Environmental Determinants of Autoimmune Diseases*, June, 1998

BIBLIOGRAPHY

Primary Peer-Reviewed Publications

1. Ilan, J, Pierce DR, **Miller, FW**. Influence of 9-beta-d-arabino furanosyladenine on total protein synthesis and on differential gene expression of unique proteins in the rodent malarial parasite *Plasmodium berghei*. *Proc Natl Acad Sci U.S.A.* 1977; 74(8):3386-90.
2. **Miller, FW**, Ilan J. The ribosomes of *Plasmodium berghei*: isolation and ribosomal ribonucleic acid analysis. *Parasitology*. 1978; 77(3):345-65.
3. Chawla RK, **Miller FW**, Lawson DH, Nixon DW. Urinary cancer-related protein EDC1 and serum inter-alpha trypsin inhibitor in breast cancer. *Tumour Biol*. 1984; 5(6):351-63.
4. Chawla RK, Rausch DJ, **Miller FW**, Vogler WR, Lawson DH. Abnormal Profile of Serum Proteinase Inhibitors in Cancer Patients. *Cancer Res*. 1984; 44(6):2718-23.
5. **Miller FW**, Ilan J. Evidence for major differences in ribosomal subunit proteins from *Plasmodium berghei* and rat liver. *Mol Biochem Parasitol*. 1984; 12(3):249-60.
6. **Miller FW**, Santoro TJ. Nifedipine in the treatment of migraine headache and amaurosis fugax in patients with systemic lupus erythematosus (letter). *N. Engl. J. Med.* 1984; 311(14):921.
7. **Miller FW**, Baker JR, Jr., Burman KD, Steinberg, AD. Thyroid-stimulating and thyrotropin binding-inhibiting immunoglobulins in patients with systemic lupus erythematosus. In *Clinical Immunology*, 1987; Elsevier Science Publishers, Amsterdam, Eds. W. Pryzanski, M. Seligman, 73-76.
8. Biswas T, **Miller FW**, Twitty SA, Plotz PH. An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. *J Immunol Methods*. 1987; 98(2):235-41.
9. Biswas, T, **Miller FW**, Takagaki Y, Plotz PH. An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. *J Immunol Methods*. 1987; 98(2):243-8.
10. **Miller FW**, Love LA, Biswas T, McClintock PR, Notkins AL, Plotz, PH. Viral and host genetic factors influence Encephalomyocarditis virus-induced polymyositis in adult mice. *Arthritis Rheum*. 1987; 30(5):549-56.
11. **Miller FW**, Love LA. Prevention of predictable Raynaud's phenomenon with sublingual nifedipine (letter). *N. Engl. J. Med.* 1987; 317:1476.

12. **Miller FW**, Santoro TJ, Papadopoulos NM. Idiopathic anasarca associated with oligoclonal gammopathy in systemic lupus erythematosus. *J Rheum.* 1987; 14(4):842-3.
13. **Miller FW**, Moore GF, Weintraub BD, Steinberg AD. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. *Arthritis Rheum.* 1987; 30(10):1124-31.
14. Allaway GP, Srinivasappa J, **Miller FW**, Prabahakar BS, Notkins AL. Autoantibody production by human B lymphocytes which spontaneously proliferate. In *Epstein-Barr Virus and Human Diseases*, 1987; The Humana Press, P. 287-291. Eds. PH Levine.
15. Biswas T, **Miller FW**, Plotz PH. Stimulation and partial stabilization of human histidyl-tRNA synthetase by hemoglobin. *FEBS Lett.* 1988; 229(1):203-5.
16. Allaway GP, Srinivasappa J **Miller FW**, Prabhaker BS, Notkins AL. Spontaneously proliferating human B lymphocytes make autoantibodies. *J. Infectious Dis.* 1988; 157:968-972.
17. Cronin ME, Love LA, **Miller FW**, McClintock PR, Plotz PH. The natural history of Encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization. *J Exp Med.* 1988; 168(5):1639-48.
18. Cronin ME, Plotz PH, **Miller FW**. Abnormalities of the immune system in the idiopathic inflammatory myopathies. *In Vivo*, 1988; 2:25-30.
19. Cronin ME, **Miller FW**, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. *J Rheum.* 1989; 16(9):1225-8.
20. Kalovidouris AE, **Miller FW**, Lawley TJ. Polymyositis/dermatomyositis associated with dermatitis herpetiformis. *Arthritis Rheum.* 1989; 32(9):1179-81.
21. **Miller FW**. Pathogenesis, pp. 150-153, and Conclusions, p. 155. In: Plotz, PH et al., Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. *Ann. Intern. Med.* 1989; 111:143-57.
22. Tsui FW, Bernstein RM., Mathews MB, **Miller FW**. Mapping the epitopes on Jo-1 (histidyl-tRNA synthetase). *Prog Leukocyte Biol* 1989; 9: 473-6.
23. Ramsden DA, Chen J, **Miller FW**, Misener V, Bernstein RM, Siminovitch KA, Tsui FW. epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase: analysis of the myositis-associated anti-Jo-1 autoimmune response. *J Immunol.* 1989; 143(7): 2267-72.
24. Recker DP, Minor JR, **Miller FW**. Successful prevention of an anaphylactoid reaction to high-dose methotrexate. *DICP.* 1989; 23(12):1032.
25. **Miller FW**, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. *J Clin Invest.* 1990; 85(2):468-75.
26. **Miller FW**, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. *Clin Exp Immunol.* 1990; 81(3):373-9.
27. Targoff IN, Johnson AE, **Miller FW**. Antibody to signal recognition particle in polymyositis. *Arthritis Rheum.* 1990; 33(9):1361-70.

28. **Miller FW**, Waite KA, Biswas T, Plotz PH. The Role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. *Proc Natl Acad Sci U.S.A.* 1990; 87(24):9933-7.
29. Baker JR Jr, **Miller FW**, Steinberg AD, Burman KD. Thyroid stimulating and thyrotropin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. *Thyroid*. 1991; 1(3):229-34.
30. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, **Miller FW**. A New Approach to the classification of idiopathic inflammatory myopathy: myositis-specific auto-antibodies define useful homogeneous patient groups. *Medicine*, Baltimore, 1991; 70(6):360-74.
31. Fraser DD, Frank JA, Dalakas M, **Miller FW**, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. *J Rheum*. 1991; 18(11):1693-1700.
32. Leff RL, Burgess SH, **Miller FW**, Love LA, Targoff IN, Dalakas MC, Joffe MM, Plotz PH. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle auto-antibodies. *Arthritis Rheum*. 1991; 34(11):1391-6.
33. **Miller FW**, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *N Engl J Med*. 1992; 326(21):1380-4.
34. Leff, RL, Love, LA, **Miller, FW**, Greenberg, SJ, Klein, EA, Dalakas, MC, Plotz, PH. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. *Lancet*. 1992; 339(8803):1192-5.
35. **Miller FW**, Leitman SL, Plotz PH. Plasma exchange in polymyositis and dermatomyositis. (letter) *New Engl. J. Med*. 1992; 327:1030-1.
36. Fraser DD, Kong LI, **Miller FW**. Molecular detection of persistent *Borrelia burgdorferi* in a man with dermatomyositis. *Clin Exp Rheumatol*. 1992; 10(4):387-90.
37. Targoff IN, Trieu EP, Plotz PH, **Miller FW**. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. *Arthritis Rheum*. 1992; 35(7):821-30.
38. Raben N, Sherman J, **Miller FW**, Mena H, Plotz PH. A 5' splice junction mutation leading to exon deletion in an ashkenazic jewish Family with Phosphofructokinase Deficiency. *J.Biol.Chem*. 1993; 268:4963-4967
39. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, **Miller FW**. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. *Am J Med*. 1993; 94(4):379-87.
40. Targoff IN, Trieu EP, **Miller FW**. Reaction of anti-OJ auto-antibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. *J Clin Invest*. 1993; 91(6):2556-64.
41. Love LA, **Miller FW**. Non-Infectious environmental agents associated with myopathy. *Current Opinion Rheum* 1993; 5:712-718.
42. Leff RL, **Miller FW**, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. *Medicine*, Baltimore, 1993; 72(4):225-35.

43. **Miller FW**. Seasonal, geographic, clinical and immunogenetic associations of the myositis-specific autoantibodies. *Système Nerveux, Muscles et Maladies Systemiques*, 1993; Expansion Scientifique Francaise, Paris, Eds. G Serratrice.
44. Hicks JE, **Miller FW**, Plotz PH, Chen TE, Gerber L. Isometric exercise increases strength and does not produce sustained creatine kinase increases in a patient with polymyositis. *J.Rheum.* 1993; 20:1399-1401.
45. **Miller FW**. Myositis-specific autoantibodies: Touchstones for understanding the inflammatory myopathies. *JAMA*, 1993; 260:1846-1849.
46. O'Hanlon TP, Dalakas MC, Plotz PH, **Miller FW**. Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *J Immunol.* 1994; 152(5):2569-76.
47. Rider LG, **Miller FW**. New perspectives on the idiopathic inflammatory myopathies of childhood. *Current Opinion Rheum* 1994; 6:575-582.
48. O'Hanlon TP, Dalakas MC, Plotz PH, **Miller FW**. The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. *J Autoimmun.* 1994; 7(3):321-33.
49. Potter M, Morrison S, Wiener F, Zhang XK, **Miller FW**. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. *J Natl Cancer Inst.* 1994; 86(14):1058-65.
50. Rider LG, **Miller FW**, Targoff IN, Sherry DD, Samayoa E, Lindahl M, Wener MH, Pachman, LM, Plotz PH. A broadened spectrum of juvenile myositis. myositis-specific auto-antibodies in children. *Arthritis Rheum.* 1994; 37(10):1534-8.
51. Boerkoel CF, Exelbert R, Nicastrì C, Nichols RC, **Miller FW**, Plotz PH, Raben N. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. *Am J Hum Genet.* 1995; 56(4):887-97.
52. O'Hanlon TP, Raben N, **Miller FW**. A novel gene oriented in a head-to-head configuration with the human histidyl-tRNA synthetase (HRS) gene encodes an mRNA that predicts a polypeptide homologous to HRS. *Biochem Biophys Res Commun.* 1995; 2:556-66.
53. O'Hanlon TP, Messersmith WA, Dalakas MC, Plotz PH, **Miller FW**. Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *Clin Exp Immunol.* 1995; 100(3):519-28.
54. O'Hanlon TP, Dalakas MC, Plotz PH, **Miller FW**. The alpha beta T-cell receptor repertoire in idiopathic inflammatory myopathies: distinct patterns of gene expression by muscle-infiltrating lymphocytes in different clinical and serologic groups. *Ann N Y Acad Sci.* 1995; 756:410-3.
55. Rider LG, **Miller FW**. Laboratory Evaluation of the Inflammatory Myopathies. *Clinical and Diagnostic Laboratory Immunology* 1995; 2:1-9.
56. Plotz PH Rider LG, Targoff IN, Raben N, O'Hanlon TP, **Miller FW**. Myositis: Immunologic contributions to understanding cause, pathogenesis and therapy. *Annals Int. Med.* 1995; 122:715-724.
57. O'Hanlon TP, **Miller FW**. T cell-mediated immune mechanisms in myositis. *Curr. Opin. Rheum*, 1995; 7:503-509.
58. Potter M, Morrison S, **Miller FW**. Induction of plasmacytomas in genetically susceptible mice with silicone gels. *Current Topics Microbiol Immunol.* 1995; 194:83-91.

59. O'Hanlon TP, Okada S, Love LA, Dick G, Young VL, **Miller FW**. Immunohistopathology and T cell receptor gene expression in capsules surrounding silicone breast implants. *Curr Top Microbiol Immunol*. 1996; 210:237-42.
60. Rivest C, **Miller FW**, Love LA, Turgeon PP, Blier C, Senecal JL. Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. *Arthritis Rheum*. 1996; 39(7):1254-8.
61. **Miller FW**. Commentary on correlation of anti-synthetase levels with disease course in a patient with interstitial lung disease and elevation of muscle enzymes. *J. Clin. Rheum*. 1996; 2:189-191.
62. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, **Miller FW**, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. *Arthritis Rheum*. 1997; 40(7):1257-66.
63. Targoff IN, **Miller FW**, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. *Curr. Opinion of Rheumatology*, 1997; 9:527-536.
64. Rider LG, **Miller FW**. Classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheumatic Disease Clinics of North America*, 1997; 23:619-655.
65. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, Wallace CA, Ballinger SH, Bowyer SL, Reed AM, Passo MH, Katona IM, **Miller FW**, Lachenbruch PA. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *Arthritis Rheum*. 1997; 40(11):1976-83.
66. **Miller FW**, Urnovitz H. Genetic factors affecting development of autoimmunity. pp. 35-37. *Institute of Medicine Vaccine Safety Forum*. National Academy Press, 1997; Washington, DC.
67. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, **Miller FW**. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. *Arthritis Rheum*. 1998; 41(3):392-9.
68. Ginn LR, Lin JP, Plotz PH, Bale SJ, Wilder RL, Mbauya A, **Miller FW**. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. *Arthritis Rheum*. 1998; 41(3):400-5.
69. Rider LG, Gurley RC, Pandey JP, Garcia de la Torre I, Kalovidouris AE, O'Hanlon TP, Love LA, Hennekam RC, Baumbach LL, Neville HE, Garcia CA, Klingman J, Gibbs M, Weisman MH, Targoff IN, **Miller FW**. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheum*. 1998; 41(4):710-19.
70. Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, **Miller FW**, White PH, Malley JD, Rider LG. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR Imaging. *Radiology*. 1998; 209(1):191-6.
71. Rider LG, Shamim E, Okada S, Pandey JP, Targoff IN, O'Hanlon TP, Kim HA, Lim YS, Han H, Song YW, **Miller FW**. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: A tale of two loci. *Arthritis Rheum*. 1999; 42(6):1285-90.
72. Abbondanzo SL, Young VL, Wei MQ, **Miller FW**. Silicone gel-filled breast and testicular implant capsules: A histologic and immunophenotypic study. *Mod Pathol*. 1999; 12(7):706-13.

73. Centeno JA, Mullick FG, Panos RG, **Miller FW**, Valenzuela-Espinoza, A. laser-raman microprobe identification of inclusions in capsules associated with silicone gel breast implants. *Mod Pathol*. 1999; 12(7):714-21.
74. Laskin BL, Choyke P, Keenan GF, **Miller FW**, Rider LG. Novel gastrointestinal tract manifestations in juvenile dermatomyositis. *J Pediatr*. 1999; 135(3):371-4.
75. O'Hanlon TP, Lawless OJ, Katzin WE, Feng LJ, **Miller FW**. Restricted and shared patterns of TCR beta-chain gene expression in silicone breast implant capsules and remote sites of tissue inflammation. *J Autoimmun*. 2000; 14(4):283-93.
76. Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, Jimenez SA, **Miller FW**. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. *Clin Exp Immunol*. 2000; 121(1):47-52.
77. Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, **Miller FW**, Rider LG. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis Rheum*. 2000; 43(8):1866-73.
78. D'Cruz D, Keser G, Khamashta MA, Direskeneli H, Targoff IN, **Miller FW**, Hughes RVG. Anti-endothelial cell antibodies in inflammatory myopathies: distribution among clinical and serological groups and association with interstitial lung disease. *J Rheum*. 2000; 27:161-164.
79. **Miller FW**, Hess EV, Clauw DW, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA. Approaches for identifying and defining environmentally associated rheumatic disorders. *Arthritis Rheum* 2000; 43:243-249
80. Artlett CM, Ramos R, Jimenez SA, Patterson K, **Miller FW**, Rider LG. Chimeric Cells of Maternal Origin in Juvenile idiopathic inflammatory myopathies. Childhood myositis heterogeneity collaborative group. *Lancet*. 2000; 356(9248):2155-6.
81. Shamim EA, **Miller FW**. Familial autoimmunity and the idiopathic inflammatory myopathies. *Current Rheumatology Reports*, 2000; 2:201-211.
82. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, Wallace CA, Lindsley CB, Passo MH, Ballinger SH, Bowyer SL, Reed AM, White PH, Katona IM, **Miller FW**, Rider LG, Feldman BM. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the childhood health assessment questionnaire in the juvenile idiopathic myopathies. *J Rheum*. 2001; 28(5):1106-11.
83. Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, **Miller F**, Day R, Lipani J, Brooks P. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. *J Rheum*. 2001; 28: 1163-1169.
84. **Miller FW**, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg, DA. International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology*, Oxford, 2001; 40(11):1262-73.
85. Artlett CM, **Miller FW**, Rider LG. Childhood Myositis Heterogeneity Collaborative Study Group. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. *Rheumatology*, Oxford, 2001; 40(11):1279-84.

86. Richter-Reichhelm H, Stahlmann R, Smith E, Van Loveren H, Altoff J, Bass R, Corsini E, Dayan A, Dean JH, Descotes J, Emmendorffer A, Eppler R, Hall AJ, Herrman JL, Lovik M, Luster MI, **Miller FW**, Riecke K, Schoning G, Schulte A, Smialowicz RJ, Ulrich P, Vohr HW, Vos JG, White KL. Approaches to risk assessment of immunotoxic effects of chemicals. *Toxicology* 2001; 161:213-228.
87. O'Hanlon TP, **Miller FW**. Genomic Organization, Transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). *Biochem Biophys Res Commun.* 2002; 294(3):609-14.
88. Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, Burgos-Vargas R, Vazquez-Mellado J, Alcocer-Varela J, Salazar-Paramo M, Kutzbach AG, Malley JD, Targoff IN, Garcia-De la Torre I, **Miller FW**. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum.* 2002; 46(7):1885-93.
89. Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, Rennebohm RM, Passo MH, Summers RM, Hicks JE, Lachenbruch PA, Heyes MP, **Miller FW**. Juvenile Dermatomyositis Disease Activity Collaboration Study Group. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *Clinical Chemistry.* 2002; 48(10):1681-8.
90. Okada S, Weatherhead E, Targoff IN, Wesley R, **Miller FW**; International Myositis Collaborative Study Group. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. *Arthritis Rheum.* 2003; 48(8):2285-93.
91. Artlett CM, O'Hanlon TP, Lopez AM, Song YW, **Miller FW**, Rider LG. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. *Arthritis Rheum.* 2003; 48(9):2567-72.
92. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, **Miller FW**, Lachenbruch PA, Rider LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2004; 50(5):1595-603.
93. Isenberg DA, Allen E, Farewell V, Ehrenstien MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, **Miller F**. International Consensus Outcome Measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology*, Oxford, 2004; 43(1): 49-54.
94. Chanock SJ, Foster CB, **Miller FW**, O'Hanlon TP. HLA-A, -B, -Cw, -DQA1 and DRB1 in a Caucasian population from Bethesda, USA. *Human Immunology* 2004; 65:121-1223.
95. Chanock SJ, Foster CB, **Miller FW**, O'Hanlon TP. HLA-A, -B, -Cw, -DQA1 AND DRB1 in an African-American population in Bethesda, USA. *Human Immunology*, 2004; 65:1223-1235.
96. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, Hicks J, Katona IM, Lindsley CB, **Miller FW**, Passo MH, Perez MD, Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, Rider LG. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. *Arthritis Rheum.* 2004; 51(3):365-70.

97. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, **Miller FW**; International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis Rheum.* 2004; 50(6):2281-90.
98. O'Hanlon T, Koneru B, Bayat E, Love L, Targoff I, Malley J, Malley K, **Miller F**. Environmental Myositis Study Group. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. *Arthritis Rheum.* 2004; 50(11):3646-50.
99. O'Hanlon TP, Mercatante-Carrick D, Arnett FC, Reveille J, Carrington M, Oddis CV, Morel P, Malley JD, Malley K, Dreyfuss J, Shamim E, Rider LG, Chanock SJ, Foster C, Bunch T, Plotz PH, Love LA, **Miller FW**. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -C, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. *Medicine (Baltimore)* 2005; 84(6):338-49.
100. Chung Y-L, Rider LG, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, **Miller FW**, Scott DL for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005; 53(4):565-70.
101. Sarkar K, Weinberg CR, Oddis CV, Medsger TA, Plotz PH, Reveille JD, Arnett FC, Targoff IN, Genth E, Love LA, **Miller FW**. Seasonal influence in the onset of idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005; 52(8):2433-8.
102. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner H, Koneru B, Feldman BM, Giannini EH, **Miller FW** for the International Myositis Assessment and Clinical Studies Group (IMACS). International consensus guidelines for therapeutic trials in the idiopathic inflammatory myopathies, *Arthritis Rheum.* 2005; 52(9):2607-2615.
103. Römisch K, **Miller FW**, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages, *Arthritis Research & Therapy* 2006; 8(2):R39.
104. Nagaraju K, Rider LG, Fan C, Chen YW, Megan M, Rawat R, Patterson K, Grundtman C, **Miller FW**, Plotz PH, Hoffman EP, Lundberg I. Endothelial cell activation and neovascularization are prominent in dermatomyositis. *J Autoimmune Dis.* 2006; 20(1):2-8.
105. O'Hanlon TP, Mercatante-Carrick D, Targoff IN, Arnett FC, Reveille J, Carrington M, Gao X, Oddis CV, Morel P, Malley JD, Malley K, Shamim E, Rider LG, Chanock SJ, Foster C, Bunch T, Blackshear PJ, Plotz PH, Love LA, **Miller FW**. Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies: Distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 Allelic Profiles Distinguish European American Patients With Different Myositis Autoantibodies. *Medicine (Baltimore)*, 2006; 85(2):111-127.
106. Targoff IN, Mamurova G, Trieu, E Perurena, O Koneru B, O'Hanlon TP, **Miller FW***, Rider LG* for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155 kd protein is associated with dermatomyositis. *Arthritis Rheum.* 2006; 54:3682-3689 *contributed equally
107. O'Hanlon TP, Rider LG, Mamurova G, Targoff IN, Arnett FC, Reveille J, Carrington M, Gao X, Oddis CV, Morel P, Malley JD, Malley K, Shamim E, Chanock SJ, Foster C, Bunch T, Plotz PH, Love LA, **Miller FW**. HLA Polymorphisms in African Americans with idiopathic inflammatory myopathies: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies, *Arthritis Rheum.* 2006; 54:3670-3681.

108. Mamyrova G, O'Hanlon TP, Monroe J, Mercatante Carrick D, Malley J, Adams S, Reed AM, Shamim E, James Newton L, **Miller FW**, Rider LG for the Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasian patients, *Arthritis Rheum.* 2006; 54:3979-3987.
109. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, **Miller FW**, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. *Biol Blood Marrow Transplant.* 2006; 12(3):252-66.
110. Vegosen L, Weinberg C, O'Hanlon T, Targoff I, Koneru B, Mamyrova G, **Miller FW**, Rider L and the Childhood Myositis Heterogeneity Study Group. Seasonal birth patterns suggest a role for perinatal environmental factors in the etiology of subgroups of myositis, *Arthritis Rheum.* 2007; 56:2729-2739.
111. Mamyrova G, Kleiner D, Shaham B, Cartwright V, James-Newton L, **Miller FW**, Rider L. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy and pneumatosis intestinalis, *Arthritis Rheum.* 2007; 57:881-884.
112. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Lindsley CB, Reed SM, **Miller FW**, Rider LG. The Cutaneous Assessment Tool (CAT): Development and reliability in juvenile idiopathic inflammatory myopathy, *Rheumatology*, 2007; 46:1606-1611.
113. Lachenbruch PA, **Miller FW**, Rider LG. Developing international consensus on measures of improvement for myositis. *Statistical Methods in Medical Research*, 2007; 16:51-64
114. Csako G, Costello R, Shamim E, O'Hanlon T, Tran A, Clauw D, William HJ, **Miller FW**. Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study, *Arthritis Research & Therapy*, 2007, 9:R95.
115. Huber AH, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, **Miller FW**, Rider LG in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Preliminary validation and clinical meaning of the cutaneous assessment tool (CAT) in juvenile dermatomyositis. *Arthritis Rheum.* 2008; 59:214-221.
116. Huber AH, Lachenbruch PA, Dugan E, **Miller FW**, Rider L. Alternative scoring of the cutaneous assessment tool (CAT) in juvenile dermatomyositis: Results using abbreviated formats. *Arthritis Rheum.* 2008; 59:352-356.
117. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, **Miller FW**, Rider LG for the Childhood Myositis Heterogeneity Study Group. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine (Baltimore)*, 2008; 87: 70-86.
118. O'Hanlon TP, Rider LG, Schiffenbauer A, Targoff IN, Malley K, Pandey JP, **Miller FW**. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. *Arthritis Rheum.* 2008; 58: 3239-3246.

119. Mammyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, **Miller FW**, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. *Arthritis Rheum.* 2008; 58:3941-3950.
120. Burd CJ, Kinyamu HK, **Miller FW**, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. *J Biol Chem.* 2008; 283:34976-34982
121. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini R, Cabalar I, Lovell DJ, Wesley R, Plotz PH, **Miller FW**, Hicks JE, Rider LG. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis, *Rheumatology*, 2009;48:134-9.
122. Ball R, Shadomy S, Meyer A, Huber B, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer M, **Miller FW**, Braun MM. HLA type and immune response to B. burgdorferi outer surface protein A in people who developed arthritis after Lyme vaccine. *Arthritis Rheum.* 2009; 60:1179-86.
123. Love LA, Weinberg CR, McConnaughey R, Oddis CV, Medsger T, Reveille J, Arnett FC, Targoff IN, **Miller FW**. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. *Arthritis Rheum.* 2009;60:2499-504
124. Lachenbruch PA, **Miller FW**, Rider LG. On determining the effects of therapy on disease damage in non-randomized studies with multiple treatments: a study of juvenile myositis. *Communications in Statistics - Theory and Methods.* 2009;38:3268-81.
125. Rider L, Lachenbruch P, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba M, Myones BL, Pachman LM, Rennebohm RM, Reed AM, **Miller FW** for the International Myositis Assessment and Clinical Studies Group (IMACS). Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis using the Myositis Damage Index (MDI). *Arthritis Rheum.* 2009;60:3425-35.
126. Coyle K, Rother KI, Weise M, Ahmed A, **Miller FW**, Rider LG. Metabolic abnormalities and cardiovascular risk factors in children with myositis. *The Journal of Pediatrics*, 2009;155:882-7.
127. Okada S, Kamb ML, Pandey JP, Philan R, Love LA, **Miller FW**. Immunogenetic risk and protective factors for L-tryptophan associated eosinophilia-myalgia syndrome. *Arthritis Rheum.* 2009;61:1305-11.
128. Eidelman E, Boyde A, Bushby AJ, Howell PG, Sun J, **Miller FW**, Robey PG, Rider LG. Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. *Arthritis Res Ther.* 2009;11(5):R159.
129. Javierre BM, Fernandez AF, Richter J, Martin-Subero JI, Al-Shahrour F, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG, Jacinto FV, Lopez-Longo FJ, Dopazo J, Carreño L, Siebert R, Esteller M, **Miller FW**, Ballestar E. DNA methylation profiling of twins discordant for autoimmune disorders reveals targets of epigenetic deregulation in lupus. *Genome Res.* 2010;20:170-9.
130. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, **Miller FW**, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. *Arthritis Care Res.* 2010;62:465-72.

131. Rider L, Wu L, Mamyrova G, Targoff IN, **Miller FW** for the Childhood Myositis Heterogeneity Collaborative Study Group. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. *Rheumatology*, 2010;49:2381-90.
132. O'Hanlon TP, Rider LG, Gan L, Fannin R, Paules RS, Umbach DM, Weinberg C, Shah RR, Mav D, Gourley M, **Miller FW**. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. *Arth Res Ther*, 2011; 13:R69
133. Perdivara, IP, Peddada, SD, **Miller, FW**, Tomer KB, Deterding, LJ. Mass Spectrometric Determination of IgG Subclass-Specific Glycosylation Profiles in Siblings Discordant for Myositis Syndromes. *J Proteome Res*, 2011;10:2969-78.
134. Allen JA, Peterson A, Sufit R, Hinchcliff ME, Matthew Mahoney J, Wood TA, **Miller FW**, Whitfield ML, Varga J. Post-epidemic eosinophilia myalgia syndrome associated with L-tryptophan. *Arthritis Rheum*. 2011[Epub ahead of print]

Submitted manuscripts

1. O'Hanlon T, Rider L, Gourley M, **Miller FW**. Serum proteomic signatures are shared by multiple systemic autoimmune diseases: a study of monozygotic twins discordant for disease.

Books, Book Chapters, Letters and Reviews

1. Cronin ME, **Miller FW**, Plotz PH. Polymyositis and Dermatomyositis, Chapter 21, *Primer on the Rheumatic Diseases*, 1988; 9th Edition, Ed. HR Schumaker, Jr.
2. Plotz PH, **Miller, FW**. Animal models of polymyositis. *Mt.Sinai J. Med*. 1988, 55:501-505.
3. Plotz PH, Cronin ME, Love LA, **Miller FW**, McClintock P, Smith DW. Picornavirus-initiated chronic inflammation, 145-151, in *New antiviral strategies*, 1988, Churchill Livingstone, Edinburgh, Ed. SR Norrby.
4. **Miller, FW**. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. *Current Opinion Rheum*. 1991; 3:902-910.
5. Tsui FWL, **Miller FW**. Idiopathic Inflammatory Myopathies, Chapter 23 in *The Molecular Pathology of Autoimmunity*, 1993. Eds. C. Bona et al., Harwood Academic Publishers, Eds. CA Bona, K Siminovitch, AN Theofilopoulos, M Zanetti.
6. Plotz PH, Leff RL, **Miller FW**. Inflammatory and Metabolic Myopathies. Chapter 14, 127-131. In *Primer on the Rheumatic Diseases*, 1993; 10th Edition, Ed. HR Schumacher Jr.
7. Plotz PH, **Miller FW**. Etiology and Pathogenesis of Inflammatory Muscle Disease. Chapter 13, 13.1-13.10. In *Rheumatology*, 1994; Mosby, Gower Medical Publishing, London, Eds. JH Klippel, DA Dieppe.
8. **Miller FW**. Classification and prognosis of inflammatory muscle disease. *Rheumatic Disease Clinics of North America*, 1994; 20:811-826.
9. Pachman LM, **Miller FW**. Idiopathic Inflammatory Myopathies: Dermatomyositis, Polymyositis and Related Disorders. Chapter 41, pp 791-804 in *Samter's Immunologic Diseases*, 1995; Little, Brown and Company, Boston, Eds. M Frank; K Austen, H, Claman, E. Unanue

10. **Miller FW.** *Myositis - Patient Information Pamphlet*. Arthritis Foundation, Atlanta, pp. 1-8, 1995.
11. Love LA, **Miller FW**, 1995. Understanding the idiopathic inflammatory myopathies. *Contemporary Internal Medicine*. 7:29-43
12. **Miller FW**, Sawyer WR. What Causes Myositis? *National Myositis Association Newsletter* 16:2-3, 1996.
13. **Miller FW.** Genetics of autoimmune diseases. *Experimental and Clinical Immunogenetics*, 1995; 12:182-190.
14. **Miller FW.** Anti-Signal Recognition Particle Autoantibodies. In *Autoantibodies*, pp. 735-740, 1996; Elsevier Sciences BV, Amsterdam, Eds. JB Peters, Y Shoenfeld.
15. **Miller FW.** Intravenous immunoglobulin in polymyositis/dermatomyositis. In *Proceedings: Early Decisions in DMARD Development IV. Biologic Agents in Autoimmune Disease*, pp 205-212, Arthritis Foundation, 1996; Atlanta, Ed. V. Strand.
16. **Miller FW.** Inflammatory myopathies: Polymyositis, dermatomyositis, and related conditions. Chapter 73 in *Arthritis and Allied Conditions: A Textbook of Rheumatology*, pp. 1407-1432, 1996; Williams & Wilkins, Baltimore, Ed. W Koopman.
17. **Miller FW.** Editorial overview: Myositis and myopathies. *Curr. Opinion of Rheumatology*, 1996; 8:491-494.
18. Epstein S, **Miller FW.** What's in a Name? (letter). *The Scientist*, 1997; 11:9.
19. **Miller FW.** Editorial overview: Myositis and myopathies. *Curr. Opinion of Rheumatology*, 1997; 9:471-474.
20. Plotz PH, **Miller FW.** Etiology and pathogenesis of inflammatory muscle disease. Chapter 14, 14.1-14.10. In *Rheumatology*, 1997; Second Edition, Mosby, Gower Medical Publishing, London, Eds. JH Klippel and PA Dieppe.
21. **Miller FW.** Editorial overview: Myositis and myopathies. *Curr. Opinion of Rheumatology*, 1998; 10:499-503
22. **Miller FW.** Genetics of environmentally-associated rheumatic diseases. In *Rheumatic Diseases and the Environment*, 1999; Chapter 4, p 33-40, Chapman & Hall Medical Publishers, New York, Eds. L Kaufman and J Varga.
23. Cooper GS, **Miller FW**, Pandey JP. The role of genetic factors in autoimmune diseases: implications for environmental research. *Environmental Health Perspectives*, 1999; 107 (Suppl 5):693-700
24. Rider LA, **Miller FW.** Idiopathic inflammatory muscle disease: Clinical Aspects. *Bailliere's Best Practice and Research in Clinical Rheumatology* 2000; 14:37-54
25. **Miller FW**, Wortmann RL, Robbins L. *Myositis - Patient Information Pamphlet*. Arthritis Foundation, Atlanta, 2000.
26. Shamim EA, Rider LG, **Miller FW.** Update on the genetics of the idiopathic inflammatory myopathies. *Curr. Opinion of Rheumatology*, 2000; 12: 482-491
27. Plotz PH, **Miller FW**, Hoffman E, Casciola-Rosen L, Rosen, A. Workshop on inflammatory myopathy, Bethesda, 5-6 April 2000; *Neuromuscul Disord* 2001; 11:93-95
28. **Miller FW.** Inflammatory myopathies: Polymyositis, dermatomyositis, and related conditions. In *Arthritis and Allied Conditions, A Textbook of Rheumatology*, 2000, 14th Edition, Chapter 78, 1562-1589 (volume 2), Lippincott, Williams, and Wilkins, Philadelphia, Ed. W. Koopman.

29. Pachman LM, **Miller FW**. Idiopathic inflammatory myopathies: Dermatomyositis, polymyositis and related disorders. In *Samter's Immunologic Diseases*, 6th Ed, 2001, Chapter 41, pp 791-804, Little, Brown and Company, Boston, Eds. K F Austen, MM Frank, JP Atkinson, H Cantor.
30. Plotz PH, **Miller FW**. Myositis classics: An historical perspective at the millennium. In *Classic Papers in Rheumatology*, 2001, Martin Dunitz, London. Chapter 15, Pages 222-235, Ed. P Dieppe et al.
31. Cooper GS, **Miller FW**, Germolec DR. Occupational exposures and autoimmune diseases. *International Immunopharmacology*, 2002, 2: 303-313.
32. **Miller FW**, Editor. Idiopathic inflammatory myopathies, *Rheumatic Disease Clinics North America*, 2002; 28 (4).
33. **Miller FW**. Preface to idiopathic inflammatory myopathies, *Rheumatic Disease Clinics North America*, 2002; 28 (4): XI-XIII, Ed. FW Miller.
34. **Miller FW**. Myositis. In *Targeted Therapies in Rheumatology*. 2003, Martin Dunitz, London. Chapter 36, 603-620, Eds. JS Smolen and PE Lipsky.
35. Henderson C, **Miller FW**, Minor M. Wortmann RL. Myositis - Patient information pamphlet. Arthritis Foundation, 2003, Atlanta, pp. 1-7.
36. **Miller FW**. Inflammatory Myopathies: Polymyositis, dermatomyositis, and related conditions. In *Clinical Primer of Rheumatology*. 2003, Chapter 15, 182-198, Lippincott, Williams, and Wilkins, Philadelphia, Eds. WJ Koopman, DW Boulware, GR Huebert.
37. Rider L, Giannini E, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch P, **Miller FW**. Defining clinical improvement in adult and juvenile myositis. *J Rheumatol* 2003, 30: 603-17.
38. Nagaraju K, Plotz PH, **Miller FW**. Etiology and pathogenesis of inflammatory muscle disease. Chapter 138, 1523-1535. In *Rheumatology*, Third Edition, 2003; Mosby, Elsevier Limited, London, Eds. MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman.
39. **Miller FW**, Rider, LG, Plotz, PH, Isenberg, DA, Oddis, CV. Diagnostic criteria for polymyositis and dermatomyositis. *Lancet*. 2003; 362(9397):1762-3 (letter).
40. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, **Miller FW**. International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis. *J Rheumatol*. 2003; 30(3):603-17.
41. **Miller FW**. Polymyositis and Dermatomyositis, Chapter 283, 1680-1684, In *Cecil Textbook of Medicine*, 22nd Edition, 2004; Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
42. **Miller FW**, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV. Polymyositis: An overdiagnosed entity. *Neurology* 2004; 63:402 (letter).
43. Sarkar K, **Miller FW**. Possible roles and determinants of microchimerism in autoimmune and other disorders. *Autoimmun Rev*. 2004; 3:454-63.
44. **Miller FW**. Myositis. Chapter 10, 187-201. In *The Year in Rheumatic Disorders*, 2004; Volume 4, Clinical Publishing, Oxford, Eds. R Madhok and H Capell.
45. Sarkar K, **Miller FW**. Autoantibodies as Predictive and Diagnostic Markers of Idiopathic Inflammatory Myopathies. *Autoimmunity*. 2004; 37(4):291-4.

46. Kerns W, Schwartz L, Blanchard K, Burchiel S, Essayan D, Fung, E, Johnson R, Lawton M, Loudon C, MacGregor J, **Miller FW**, Nagarkatti P, Robertson D, Sistare F, Snyder, P, Thomas H, Wagner B, Ward A, Zhang, J (FDA Expert Working Group on Drug-Induced Vascular Injury). Drug-Induced Vascular Injury—A quest for biomarkers. *Toxicology and Applied Pharmacology*, 2004; 203(1): 62-87.
47. **Miller F.W.** Clinical presentation and therapy of the idiopathic inflammatory myopathies. *Journal of Musculoskeletal Pain*, 2004; 12:85-91.
48. **Miller FW.** Inflammatory Myopathies: Polymyositis, dermatomyositis, and related conditions. In *Arthritis and Allied Conditions - A Textbook of Rheumatology*, 2005; 15th Edition, Chapter 75 (volume 2), 1593-1620. Lippincott Williams & Wilkins, Philadelphia, Eds. W Koopman, L Moreland.
49. Huber AM, **Miller FW**, Rider LG. Validation and clinical significance of the Childhood Myositis Assessment Scale – Reply, *Arthritis Rheum*, 2005; 52:368-369 (letter).
50. **Miller FW.** Non-infectious Environmental Agents and Autoimmunity. Chapter 23. *The Autoimmune Diseases*, 2006; 297-308, Elsevier, Boston; 4th Edition, Eds. NR Rose, IR Mackay.
51. **Miller FW.** Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis? *Nature Clinical Practice Rheumatology*, Practice Point Commentary, 2006; 2(3):130-131.
52. O’Hanlon TP, **Miller FW.** The Idiopathic Inflammatory Myopathies (IIM): HLA polymorphisms distinguish patients with different clinical phenotypes and myositis-specific autoantibodies, *ASHI Quarterly*, 2006; Fourth quarter: 98-100.
53. **Miller FW.** How do we best define autoantibodies? *Ann Rheum Dis*, 2006; eLetter <http://ard.bmjournals.com/cgi/eletters/65/2/242#521>.
54. Cooper GS, **Miller FW.** Environmental influences on autoimmunity and autoimmune diseases. Chapter 25, In *Immunotoxicology and Immunopharmacology*, 2007; 437-454, CRC Press, New York, 3rd Edition, Eds. R Luebke et al.
55. Rider LG, Pachman L, **Miller FW**, Bollar H, Editors. *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; 1-466, The Myositis Association, Washington DC.
56. Rider LG, Pachman LM, **Miller FW**, Bollar H. Introduction. *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers*. 2007;1-8, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
57. Rider LG, **Miller FW.** What Is Juvenile Myositis?, Chapter 1, In *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; 9-22, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
58. **Miller FW**, Lovell D. New Therapies on the Horizon. Chapter 15, In *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; 207-216, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
59. Lovell D, **Miller FW.** How We Learn About Juvenile Myositis? Chapter 39, In *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; 423-434, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
60. Gourley M, **Miller FW.** Mechanisms of Disease: Environmental factors in the pathogenesis of rheumatic disease. *Nature Clinical Practice Rheumatology* 2007; 3:172-180

61. **Miller FW.** Myositis, Chapter 38, In *Contemporary Targeted Therapies in Rheumatology*, 2007; 467-484, Informa Healthcare, London, Eds. JS Smolen and PE Lipsky.
62. Rider LG, **Miller FW.** Idiopathic inflammatory myopathies, Pathology and pathogenesis, Chapter 18B, *Primer on the Rheumatic Diseases*, Thirteenth Edition, 2007; 368-374, Springer, Arthritis Foundation, New York, Eds. J. Klippel et al.
63. **Miller FW**, Cooper GS. Environmental aspects of lupus, Chapter 3, *Dubois' Lupus Erythematosus*. 2007; 21-33, 7th Edition; Lippincott Williams and Wilkins, Philadelphia, Eds. D Wallace, B Hahn.
64. **Miller FW.** Idiopathic inflammatory myopathies. Chapter 15.6, In *American College of Physicians ACP Medicine online*, 2007 WebMD Professional Publishing, New York, Ed. S. Ruddy
65. Rider LG, Lachenbruch P, Isenberg DA, **Miller FW.** Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. *Arthritis Rheum.* 2008;59:1197-1198 (letter).
66. **Miller FW.** Polymyositis and dermatomyositis, Chapter 290, In *Cecil Textbook of Medicine*, 2008; 23rd Edition; 2045-2049, Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
67. Dugan EM, Huber A, **Miller FW**, Rider LG for the International Myositis Assessment and Clinical Studies Group (IMACS). Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatology Online Journal*, 2009;15 (2) 1. <http://dermatology-s10.cdlib.org/1502/reviews/photoessay/riderphotos.html>.
68. Dugan EM, Huber A, **Miller FW**, Rider LG for the International Myositis Assessment and Clinical Studies Group (IMACS). Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatology Online Journal*, 2009;15 (2) 2. <http://dermatology-s10.cdlib.org/1502/reviews/photoessay/rideressay.html>.
69. O'Hanlon, TP, **Miller, FW.** Genetic risk and protective factors for the idiopathic inflammatory myopathies. *Curr Rheum Reports*, 2009; 11: 287-94.
70. **Miller, FW.** Classification of the idiopathic inflammatory myopathies, Chapter 2 in *The Inflammatory Myopathies*, 2009; 15-28, Humana Press, Springer, New York, Ed. L. Kagen.
71. Targoff IN, Oddis C, Plotz P, **Miller FW**, Gourley M. Inflammatory Myopathies. In *A Clinician's Pearls and Myths in Rheumatology*, Springer, New York, Ed. John Stone, 2009;191-99.
72. Rider LG, **Miller FW.** Mast cells and type I interferon responses in the skin of juvenile dermatomyositis: Are current therapies just scratching the surface? *Arthritis Rheum.* 2010; 62:2619-22
73. **Miller, F.W.** Management of Inflammatory Muscle Disease. Chapter 146, In *Rheumatology*, 5th Edition, Elsevier, Philadelphia, Eds. Hochberg et al. 2011, 1417-78.
74. Rider, L.G and **Miller, F.W.** Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. *JAMA*, 2011; 305:183-90.
75. **Miller, F.W.** Environmental Agents and Autoimmune Diseases, In *Epigenetic Contributions in Autoimmune Disease*, Landes Bioscience, Austin, Ed. E. Ballestar; part of the series: *Advances in Experimental Medicine and Biology* (2011); 711: 61-81.
76. Whitt, I.Z. and **Miller, F.W.** Inflammatory myopathies: polymyositis, dermatomyositis and related conditions, Chapter 13 in *Lippincott's Primary Care Rheumatology*, Lippincott, Williams and Wilkins, Philadelphia, Ed. D.W. Boulware and G.R. Heudebert, *in press*

77. **Miller, F.W.** Idiopathic Inflammatory Myopathies, In *American College of Physicians ACP Medicine*, WebMD Professional Publishing, New York, Ed. E. Nabel, *in press*
78. **Miller, F.W.** and Oddis, C.V. Vasculitis in the Idiopathic Inflammatory Myopathies, In *Inflammatory Diseases of Blood Vessels*, 2nd Edition, Blackwell Publishing Limited, Oxford. Ed. Gary Hoffman et al., *in press*.
79. **Miller FW.** Polymyositis and dermatomyositis, Chapter 277, In *Cecil Textbook of Medicine*, 2011; 24th Edition; , Saunders, Philadelphia, Eds. L Goldman, D Ausiello., *in press*